{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-037601","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.988108+00:00","generated_at":"2026-05-17T20:35:39.247387+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Esperion Q2 revenue $82.4M (+12% Y/Y); first operating income of $15M; expects sustainable profitability Q1 2026","bullets":["U.S. net product revenue $40.3M, +42% Y/Y; total prescriptions up 10% sequential.","Net loss per share $0.02 vs $0.33 loss a year ago; operating income from ongoing business $15M.","Reached settlements with three ANDA filers to block generic NEXLETOL until 2040.","Royalty revenue from European partner up 30% sequentially to $13.6M; Japan approval on track for H2 2025.","Reiterated FY2025 opex $215-235M; cash $86.1M; shares outstanding ~200.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-037601","json":"https://secwatch.observer/filing/0001628280-25-037601.json","markdown":"https://secwatch.observer/filing/0001628280-25-037601.md","text":"https://secwatch.observer/filing/0001628280-25-037601.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025037601/0001628280-25-037601-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828025037601/espr-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:35:39.247387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}